"Hyperlipidemias" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Conditions with excess LIPIDS in the blood.
| Descriptor ID |
D006949
|
| MeSH Number(s) |
C18.452.584.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hyperlipidemias".
Below are MeSH descriptors whose meaning is more specific than "Hyperlipidemias".
This graph shows the total number of publications written about "Hyperlipidemias" by people in this website by year, and whether "Hyperlipidemias" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2008 | 3 | 0 | 3 |
| 2014 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2017 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hyperlipidemias" by people in Profiles.
-
Management of hyperlipidaemia. S Afr Med J. 2024 Mar 18; 114(3):e1016.
-
ANGPTL3 as a Drug Target in Hyperlipidemia and Atherosclerosis. Curr Atheroscler Rep. 2022 12; 24(12):959-967.
-
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017 Aug 21; 38(32):2459-2472.
-
Glycaemic, blood pressure and cholesterol control in 25 629 diabetics. Cardiovasc J Afr. 2015 Jul-Aug; 26(4):188-92.
-
Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials. Eur Heart J. 2014 Sep 01; 35(33):2249-59.
-
The evaluation of low-density lipoprotein cholesterol goals achieved in patients with established cardiovascular disease and/or hyperlipidaemia receiving lipid-lowering therapy: the South African Not at Goal study (SA-NAG). Cardiovasc J Afr. 2008 Mar-Apr; 19(2):88-94.
-
Questioning the importance of LDL cholesterol: don't throw the baby out with the bathwater! Cardiovasc J Afr. 2008 Mar-Apr; 19(2):63-4.
-
Postprandial lipaemia, metabolic syndrome and LDL particle size in urbanised South African blacks with and without coronary artery disease. QJM. 2008 Feb; 101(2):111-9.
-
Atazanavir: a review of its use in the management of HIV infection. Drugs. 2005; 65(16):2309-36.
-
A single-centre retrospective observational study to evaluate the change in total cholesterol and LDL cholesterol in hyperlipidaemic patients switched from atorvastatin to simvastatin. Cardiovasc J S Afr. 2004 May-Jun; 15(3):118-23.